Hyaluronan as a promising excipient for ocular drug delivery
[Display omitted] Hyaluronan (HA) is a naturally occurring polysaccharide and well known for its exceptional properties such as high biocompatibility and biodegradability, along with a low immunogenicity. Besides its use for various biomedical applications it recently came into focus as a favorable...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmaceutics and biopharmaceutics 2017-04, Vol.113, p.34-49 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 49 |
|---|---|
| container_issue | |
| container_start_page | 34 |
| container_title | European journal of pharmaceutics and biopharmaceutics |
| container_volume | 113 |
| creator | Guter, Michaela Breunig, Miriam |
| description | [Display omitted]
Hyaluronan (HA) is a naturally occurring polysaccharide and well known for its exceptional properties such as high biocompatibility and biodegradability, along with a low immunogenicity. Besides its use for various biomedical applications it recently came into focus as a favorable excipient for the formulation of various ocular therapeutics. This review article summarizes the ocular distribution of HA and its most heavily investigated binding protein “cluster of differentiation 44” (CD44) which is the rationale for the clinical use of HA, primarily as an additive in ocular applications ranging from eye drops to contact lenses. Moreover, examples will be given for using HA in various pre-clinical approaches to generate entirely new therapeutics, most notably in the field of nanotechnology. |
| doi_str_mv | 10.1016/j.ejpb.2016.11.035 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1846028711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641116303976</els_id><sourcerecordid>1846028711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-1075229b40c328ed67bb7068bf5dc66c79e03cf675c854ae4a6bf2dae07701593</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwBxhQRpYEnz8TqQtCfEmVWGC2HOdSuUqTYjcV_fe4KjAy3Q3P--ruIeQaaAEU1N2qwNWmLljaC4CCcnlCplBqnnMh4JRMacWrXAmACbmIcUUpFVqW52TCdAWCcTkl85e97cYw9LbPbMxstgnD2kffLzP8cn7jsd9m7RCywY2dDVkTxmXWYOd3GPaX5Ky1XcSrnzkjH0-P7w8v-eLt-fXhfpE7LtU2B6olY1UtqOOsxEbputZUlXUrG6eU0xVS7lqlpSulsCisqlvWWKRaU5AVn5HbY2867nPEuDXpRIddZ3scxmigFIqyUgMklB1RF4YYA7ZmE_zahr0Bag7WzMocrJmDNQNgkrUUuvnpH-s1Nn-RX00JmB8BTF_uPAYTXTLjsPEB3dY0g_-v_xvCE301</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1846028711</pqid></control><display><type>article</type><title>Hyaluronan as a promising excipient for ocular drug delivery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Guter, Michaela ; Breunig, Miriam</creator><creatorcontrib>Guter, Michaela ; Breunig, Miriam</creatorcontrib><description>[Display omitted]
Hyaluronan (HA) is a naturally occurring polysaccharide and well known for its exceptional properties such as high biocompatibility and biodegradability, along with a low immunogenicity. Besides its use for various biomedical applications it recently came into focus as a favorable excipient for the formulation of various ocular therapeutics. This review article summarizes the ocular distribution of HA and its most heavily investigated binding protein “cluster of differentiation 44” (CD44) which is the rationale for the clinical use of HA, primarily as an additive in ocular applications ranging from eye drops to contact lenses. Moreover, examples will be given for using HA in various pre-clinical approaches to generate entirely new therapeutics, most notably in the field of nanotechnology.</description><identifier>ISSN: 0939-6411</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2016.11.035</identifier><identifier>PMID: 27914235</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Ophthalmic ; Drug Delivery Systems ; Excipients ; Eye - anatomy & histology ; Humans ; Hyaluronan Receptors - chemistry ; Hyaluronic Acid - administration & dosage ; Hyaluronic Acid - chemistry</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2017-04, Vol.113, p.34-49</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-1075229b40c328ed67bb7068bf5dc66c79e03cf675c854ae4a6bf2dae07701593</citedby><cites>FETCH-LOGICAL-c356t-1075229b40c328ed67bb7068bf5dc66c79e03cf675c854ae4a6bf2dae07701593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0939641116303976$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27914235$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guter, Michaela</creatorcontrib><creatorcontrib>Breunig, Miriam</creatorcontrib><title>Hyaluronan as a promising excipient for ocular drug delivery</title><title>European journal of pharmaceutics and biopharmaceutics</title><addtitle>Eur J Pharm Biopharm</addtitle><description>[Display omitted]
Hyaluronan (HA) is a naturally occurring polysaccharide and well known for its exceptional properties such as high biocompatibility and biodegradability, along with a low immunogenicity. Besides its use for various biomedical applications it recently came into focus as a favorable excipient for the formulation of various ocular therapeutics. This review article summarizes the ocular distribution of HA and its most heavily investigated binding protein “cluster of differentiation 44” (CD44) which is the rationale for the clinical use of HA, primarily as an additive in ocular applications ranging from eye drops to contact lenses. Moreover, examples will be given for using HA in various pre-clinical approaches to generate entirely new therapeutics, most notably in the field of nanotechnology.</description><subject>Administration, Ophthalmic</subject><subject>Drug Delivery Systems</subject><subject>Excipients</subject><subject>Eye - anatomy & histology</subject><subject>Humans</subject><subject>Hyaluronan Receptors - chemistry</subject><subject>Hyaluronic Acid - administration & dosage</subject><subject>Hyaluronic Acid - chemistry</subject><issn>0939-6411</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQhi0EoqXwBxhQRpYEnz8TqQtCfEmVWGC2HOdSuUqTYjcV_fe4KjAy3Q3P--ruIeQaaAEU1N2qwNWmLljaC4CCcnlCplBqnnMh4JRMacWrXAmACbmIcUUpFVqW52TCdAWCcTkl85e97cYw9LbPbMxstgnD2kffLzP8cn7jsd9m7RCywY2dDVkTxmXWYOd3GPaX5Ky1XcSrnzkjH0-P7w8v-eLt-fXhfpE7LtU2B6olY1UtqOOsxEbputZUlXUrG6eU0xVS7lqlpSulsCisqlvWWKRaU5AVn5HbY2867nPEuDXpRIddZ3scxmigFIqyUgMklB1RF4YYA7ZmE_zahr0Bag7WzMocrJmDNQNgkrUUuvnpH-s1Nn-RX00JmB8BTF_uPAYTXTLjsPEB3dY0g_-v_xvCE301</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Guter, Michaela</creator><creator>Breunig, Miriam</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201704</creationdate><title>Hyaluronan as a promising excipient for ocular drug delivery</title><author>Guter, Michaela ; Breunig, Miriam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-1075229b40c328ed67bb7068bf5dc66c79e03cf675c854ae4a6bf2dae07701593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Ophthalmic</topic><topic>Drug Delivery Systems</topic><topic>Excipients</topic><topic>Eye - anatomy & histology</topic><topic>Humans</topic><topic>Hyaluronan Receptors - chemistry</topic><topic>Hyaluronic Acid - administration & dosage</topic><topic>Hyaluronic Acid - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guter, Michaela</creatorcontrib><creatorcontrib>Breunig, Miriam</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guter, Michaela</au><au>Breunig, Miriam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyaluronan as a promising excipient for ocular drug delivery</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><addtitle>Eur J Pharm Biopharm</addtitle><date>2017-04</date><risdate>2017</risdate><volume>113</volume><spage>34</spage><epage>49</epage><pages>34-49</pages><issn>0939-6411</issn><eissn>1873-3441</eissn><abstract>[Display omitted]
Hyaluronan (HA) is a naturally occurring polysaccharide and well known for its exceptional properties such as high biocompatibility and biodegradability, along with a low immunogenicity. Besides its use for various biomedical applications it recently came into focus as a favorable excipient for the formulation of various ocular therapeutics. This review article summarizes the ocular distribution of HA and its most heavily investigated binding protein “cluster of differentiation 44” (CD44) which is the rationale for the clinical use of HA, primarily as an additive in ocular applications ranging from eye drops to contact lenses. Moreover, examples will be given for using HA in various pre-clinical approaches to generate entirely new therapeutics, most notably in the field of nanotechnology.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27914235</pmid><doi>10.1016/j.ejpb.2016.11.035</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-6411 |
| ispartof | European journal of pharmaceutics and biopharmaceutics, 2017-04, Vol.113, p.34-49 |
| issn | 0939-6411 1873-3441 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1846028711 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Ophthalmic Drug Delivery Systems Excipients Eye - anatomy & histology Humans Hyaluronan Receptors - chemistry Hyaluronic Acid - administration & dosage Hyaluronic Acid - chemistry |
| title | Hyaluronan as a promising excipient for ocular drug delivery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T14%3A00%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyaluronan%20as%20a%20promising%20excipient%20for%20ocular%20drug%20delivery&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=Guter,%20Michaela&rft.date=2017-04&rft.volume=113&rft.spage=34&rft.epage=49&rft.pages=34-49&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2016.11.035&rft_dat=%3Cproquest_cross%3E1846028711%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1846028711&rft_id=info:pmid/27914235&rft_els_id=S0939641116303976&rfr_iscdi=true |